The oral biologics revolution: How macrocyclic peptides could reshape drug delivery
Macrocyclic peptides are revolutionizing oral biologics. Explore how Merck, Protagonist, and others are turning injectables into convenient, high-impact pills. Read More
Can IonQ become the Nvidia of quantum computing? What the Oxford Ionics deal signals about platform consolidation
IonQ’s deal to acquire Oxford Ionics marks a strategic shift toward becoming the “Nvidia of quantum.” Explore what this means for quantum computing’s future. Read More
Quantum leap: IonQ targets Oxford Ionics in $1bn+ deal to hit 2 million qubits by 2030
IonQ’s $1.075B acquisition of Oxford Ionics boosts its bid for fault-tolerant quantum systems by 2030. Find out what this means for the industry. Read More
How AI is transforming cancer diagnosis and treatment planning in 2025
AI is reshaping cancer care—improving diagnosis, guiding treatment, and boosting efficiency across hospitals. Discover how it's redefining oncology workflows in 2025. Read More
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market. Read More
Racing to save lives: Indy 500 and NASCAR drivers unite to fight prostate cancer in veterans
Find out how ZERO Prostate Cancer and racing legends are spotlighting veterans’ health at Indy 500 and NASCAR this Memorial Day weekend. Read More
AstraZeneca’s $13.6bn Q1 2025 sales surge as cancer drugs and AI deals set stage for $80bn goal
Explore how AstraZeneca’s strong Q1 2025 results, new drug approvals, and AI-powered R&D are reshaping its global growth story. Read More
Imfinzi gains EU approval in resectable NSCLC, bolstering AstraZeneca’s oncology pipeline
AstraZeneca’s Imfinzi-based regimen approved in the EU to cut lung cancer recurrence by 32%—learn how this could redefine early-stage NSCLC treatment. Read More
EU approves Enhertu as first HER2-targeted therapy for HR-positive, HER2-low metastatic breast cancer
Discover how Enhertu’s EU approval is transforming care for HR-positive, HER2-low and HER2-ultralow breast cancer, and what it means for AstraZeneca’s future. Read More
AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing
AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy. Read More